Speaker Profile
CEO, datma
Biography
Noah Nasser is a healthcare executive with over 30 years of experience in biotechnology, genomics, and molecular diagnostics. He is leading efforts to revolutionize healthcare through innovative data solutions, including the launch of a federated real-world data marketplace that enables secure, scalable collaboration and data sharing between custodians and consumers. Previously, Noah was CEO of Serimmune, where he led the company through multiple funding rounds and launched its immuno-mapping technology. He has held senior leadership roles at Human Longevity, Inc., Counsyl, AltheaDx, Verinata Health, and Quidel Corporation, driving commercialization and business growth. Known for his ability to innovate and scale businesses, Noah is positioned to shape the future of healthcare data. He is also an Executive in Residence at the University of Utahs Center for Technology and Commercialization.
Session Abstract – PMWC 2026 Silicon Valley
Track Co-Chairs:
- William Oh, Yale Cancer Center
- David Reese, Amgen
Patient-centric data, such as Real-World Evidence (RWE) and Real-World Data (RWD), has become critical in reshaping drug development and healthcare decision-making. Over the last few years, regulatory agencies like the FDA and EMA have increasingly embraced RWE/RWD for decision-making processes, influencing everything from new drug indications to post-marketing surveillance. The integration of RWE and RWD is not only supporting clinical trial design and regulatory approvals, but also enabling precision medicine by providing deeper insights into patient subpopulations and their outcomes
Sessions:
- TBA
